Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis

Inclusion Criteria: * Alcoholic cirrhotics between 18-65 years of age (diagnosed by clinical, biochemical, sonographic, radiological \[CT scan\] or histological evidence of cirrhosis and portal hypertension). * Evidence of decompensated liver disease at screening (e.g. Child class B or C, Child-Pugh scores of ≥7 and \<14). * MELD scores of at least 10 (UNOS Meld calculator). * Normal AFP Level * Hb\>10gm/dl. * Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study * Signed informed consent. Exclusion Criteria: * Patients likely to undergo liver transplantation during the duration of the study. * Presence of advanced hepatic encephalopathy Grades 3 \& 4 (West Haven criteria for grading of hepatic encephalopathy) at the time of screening * Active variceal bleed. * Refractory ascites. * Evidences of autoimmune liver disease- ANA or Anti-LKM positivity. * Platelet count \< 30,000/mm3. * Serum Sodium \<129mEq/L. * Serum Creatinine \> 2 mg/dl. * Hepatocellular carcinoma or other malignancies * Active infectious disease. * Presence of severe underlying cardiac, pulmonary or renal disease. * Excessive alcohol (\>30 gm of alcohol/day) use in the last 3 months before screening. * Positive HbSAg or antibodies to HIV or HCV. * Pregnancy or lactation. * Participation in other clinical trials. * Unwilling/unable to sign the informed consent.